Protagenic Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.22 Insider Own0.90% Shs Outstand17.28M Perf Week-14.78%
Market Cap9.71M Forward P/E- EPS next Y- Insider Trans25.39% Shs Float13.90M Perf Month-23.37%
Income-3.80M PEG- EPS next Q- Inst Own9.10% Short Float0.31% Perf Quarter-16.72%
Sales- P/S- EPS this Y-24.50% Inst Trans-4.27% Short Ratio1.60 Perf Half Y-29.94%
Book/sh0.48 P/B1.19 EPS next Y- ROA-36.60% Target Price- Perf Year-69.47%
Cash/sh0.52 P/C1.10 EPS next 5Y- ROE-40.70% 52W Range0.56 - 2.35 Perf YTD-58.77%
Dividend- P/FCF- EPS past 5Y6.50% ROI- 52W High-75.70% Beta-
Dividend %- Quick Ratio19.50 Sales past 5Y- Gross Margin- 52W Low1.87% ATR0.06
Employees- Current Ratio19.50 Sales Q/Q- Oper. Margin- RSI (14)32.99 Volatility10.12% 8.56%
OptionableNo Debt/Eq0.04 EPS Q/Q63.90% Profit Margin- Rel Volume1.34 Prev Close0.62
ShortableYes LT Debt/Eq0.04 Earnings- Payout- Avg Volume26.76K Price0.57
Recom2.00 SMA20-14.93% SMA50-14.23% SMA200-35.43% Volume35,772 Change-7.90%
Apr-26-22 08:15AM
Nov-16-21 09:58AM
Aug-30-21 09:15AM
Aug-17-21 07:45AM
Jul-23-21 04:21PM
11:20AM Loading…
Jul-08-21 11:20AM
Jul-06-21 06:17AM
Jun-23-21 09:35AM
Jun-16-21 09:15AM
Apr-29-21 03:06PM
Apr-26-21 08:58PM
Dec-16-20 09:15AM
Sep-08-20 12:10PM
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Arrow Alexander K.Chief Financial OfficerMay 18Buy0.728,0005,760151,260May 18 05:11 PM
Arrow Alexander K.Chief Financial OfficerMay 17Buy0.7123,00016,330143,260May 18 05:11 PM